Panelists:
Ehsan Malek, MD
Associate Professor of Medicine
Director of the Multiple Myeloma Translational Research Program
Roswell Park Comprehensive Cancer Center
Juan José Garcés, PhD
Postdoctoral Researcher
Memorial Sloan Kettering Cancer Center
C. Michael Osborne, MS, CGC
Medical Science Liaison
Menarini Silicon Biosystems
- Time:
Plasma cell neoplasms, including multiple myeloma (MM), collectively represent the third most diagnosed hematologic malignancy in the United States. Although primarily a disease of the bone marrow, plasma cell neoplasms frequently exhibit peripheral egression, with circulating multiple myeloma cells (CMMCs) detectable in the blood of about 98% of newly diagnosed patients.
A growing body of evidence demonstrates that CMMCs reflect overall disease biology—including bone marrow tumor burden, underlying genomic architecture, and disease activity. These findings support the continued deployment of minimally invasive, guideline-acknowledged complementary tools for assessing patient prognostication, disease progression and remission monitoring, and assessment of treatment response.
In this Inside Precision Medicine webinar, our expert speakers will discuss the rapidly evolving landscape of multiple myeloma diagnosis, treatment, and monitoring—with an emphasis on advancements in minimally invasive, guideline-acknowledged tools. During the webinar, they will explore the clinical utilities of peripheral blood plasma cell enumeration in multiple myeloma and its precursor conditions. They will also review anticipated updates to the International Myeloma Working Group (IMWG) Disease Response Criteria, including a new response category that requires an assessment for circulating plasma cells as part of its revised multimodal monitoring approach.
A live Q&A session followed the presentation offering a chance to pose questions to our expert panelists.
Produced with support from:







